Codexis

Company CDXS

Last mentioned: Mar 24, 2026

Timeline

  1. Analyst Sentiment Review

    Major firms maintain ratings, citing steady execution of the strategic pivot.

  2. 2026 Guidance Issued

    Management outlines $72M-$76M revenue target driven by ECO Synthesis.

  3. Q4 2025 Earnings Release

    Codexis reports significant beats on both top and bottom lines.

Stories mentioning Codexis 3

pharma Neutral

Wall Street Zen Upgrades Codexis and Enovis on Strong 2026 Growth Outlooks

Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.

2 sources
pharma Bullish

Biotech Sector Pivots: Codexis, Elutia, and Biote Signal Strategic Shifts

Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.

9 sources

About Codexis coverage

This page surfaces every story mentioning Codexis across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Codexis was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.